The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-analyses of 287 secondary prevention trials and 6 primary prevention trials. The present document intends to provide practicing physicians with an updated instrument to guide their choice of the most suitable antiplatelet strategy for the individual patient at risk, or with different clinical manifestations, of atherothrombosis.

Original publication

DOI

10.1093/eurheartj/ehr373

Type

Journal article

Journal

Eur Heart J

Publication Date

12/2011

Volume

32

Pages

2922 - 2932

Keywords

Coronary Artery Disease, Coronary Thrombosis, Drug Therapy, Combination, Humans, Platelet Activation, Platelet Aggregation Inhibitors, Risk Factors